Overexpression of IRS-4 Correlates with Procaspase 3 Levels in Tumoural Tissue of Patients with Colorectal Cancer
Affiliations
We reported that insulin receptor substrate 4 (IRS-4) levels increased in tissue from colorectal cancer (CRC) patients and promoted retinoblastoma-cyclin-dependent kinase activation. The aim of the present study was to evaluate the effect of IRS-4 on IGF-1 receptor pathway and its impact on procaspase 3 and PARP expression in RKO and HepG2 cancer cell lines. The results obtained were compared with those obtained from biopsies of patients with CRC (n = 18), tubulovillous adenomas (TA) (n = 2) and in matched adjacent normal colorectal (MANC) tissue (n = 20). IRS-4 overexpression in cultured cells induced the overactivation of IGF-1/BRK/AKT/GSK-3/-catenin/cyclin D1 pathways, which led to increased expression of procaspase 3 and PARP protein levels. Studies carried out on CRC and TA tissues revealed the overactivation of the IGF-1 receptor signalling pathway, as well as the overexpression of procaspase 3 and PARP in tumoural tissue with respect to MANC tissue. The upregulation of IRS-4 in tumoural samples correlated significantly with the increase in pIGF-1 receptor (Tyr 1165/1166) (r = 0.84; p < 0.0001), procaspase 3 (r = 0. 77; p < 0. 0005) and PARP (r = 0. 89; p < 0. 0005). Similarly, we observed an increase in the proteolysis of procaspase 3 in tumoural tissue with respect to MANC tissue, which correlated significantly with the degradation of PARP (r = 0.86; p < 0.0001), p53 (r = 0.84; p < 0.0001), and GSK-3 (r = 0.78; p < 0.0001). The stratification of patient samples using the TNM system revealed that procaspase 3 and caspase 3 increased gradually with T values, which suggests their involvement in the size and local invasion of primary tumours. Taken together, our findings suggest that IRS-4 overexpression promotes the activation of the IGF-1 receptor pathway, which leads to the increase in procaspase 3 levels in CRC.
Moss C, Wilson A, Reed K, Jennings K, Kunz I, Landolt G Animals (Basel). 2024; 14(16).
PMID: 39199837 PMC: 11350661. DOI: 10.3390/ani14162303.
Is Insulin Receptor Substrate4 (IRS4) a Platform Involved in the Activation of Several Oncogenes?.
Guijarro L, Justo Bermejo F, Boaru D, De Castro-Martinez P, De Leon-Oliva D, Fraile-Martinez O Cancers (Basel). 2023; 15(18).
PMID: 37760618 PMC: 10526421. DOI: 10.3390/cancers15184651.
Venous Wall of Patients with Chronic Venous Disease Exhibits a Glycolytic Phenotype.
Fraile-Martinez O, Garcia-Montero C, Alvarez-Mon M, Gomez-Lahoz A, Monserrat J, Llavero-Valero M J Pers Med. 2022; 12(10).
PMID: 36294781 PMC: 9604927. DOI: 10.3390/jpm12101642.
Ortega M, Chaowen C, Fraile-Martinez O, Garcia-Montero C, Saez M, Cruza I J Pers Med. 2022; 12(2).
PMID: 35207765 PMC: 8875350. DOI: 10.3390/jpm12020277.
Prognostic role of IRS-4 in the survival of patients with pancreatic cancer.
Ortega M, Pekarek L, Garcia-Montero C, Fraile-Martinez O, Saez M, Asunsolo A Histol Histopathol. 2022; 37(5):449-459.
PMID: 35137378 DOI: 10.14670/HH-18-432.